NCT05886998View on ClinicalTrials.gov

Nebulized Heparin for Prevention of Acute Lung Injury in Smoke Inhalation Injury

PHASE3CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 3, 2024

Study Completion Date

June 3, 2024

Conditions
Smoke Inhalation InjuryAcute Lung Injury
Interventions
DRUG

Heparin

Heparin sodium (Generic, 5000 IU/ml ampoules)

OTHER

Normal Saline

0.9% sodium chloride solution (normal saline)

Trial Locations (1)

11517

Ain Shams University Hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT05886998 - Nebulized Heparin for Prevention of Acute Lung Injury in Smoke Inhalation Injury | Biotech Hunter | Biotech Hunter